(Press-News.org) Dutch scientists have discovered five biological variants of Alzheimer's disease, which may require different treatment. As a result, previously tested drugs may incorrectly appear to be ineffective or only minimally effective. This is the conclusion of researcher Betty Tijms and colleagues from Alzheimer Center Amsterdam, Amsterdam UMC and Maastricht University. The research results will be published on 9 January in Nature Aging.
In those with Alzheimer's disease, the amyloid and tau protein clump in the brain. In addition to these clumps, other biological processes such as inflammation and nerve cells growth are also involved. Using new techniques, the researchers have been able to measure these other processes in the cerebrospinal fluid of patients with amyloid and tau clumps.
Betty Tijms and Pieter Jelle Visser examined 1058 proteins in the cerebrospinal fluid of 419 people with Alzheimer's disease. They found that there are five biological variants within this group. The first variant is characterized by increased amyloid production. In a second type, the blood-brain barrier is disrupted and there is a reduced amyloid production and less nerve cells growth. Furthermore, the variants differ in the degree of protein synthesis, the functioning of the immune system, and the functioning of the organ that produces cerebrospinal fluid. Patients with different Alzheimer's variants also showed differences in other aspects of the disease. For example, the researchers found a faster course of the disease in certain subgroups.
The findings are of great importance for drug research. It means that a drug could only work in one variant of Alzheimer's disease. For example, medication that inhibits amyloid production may work in the variant with increased amyloid production but may be harmful in the variant with decreased amyloid production. It is also possible that patients with one variant have a higher risk of side effects, while that risk is much lower with other variants. The next step for the research team is to show that the Alzheimer's variants do indeed react differently to medicines, so that we can treat everyone with appropriate medicines in the future.
END
Different biological variants discovered in Alzheimer's disease
Research from Amsterdam UMC could be essential in the evaluation of future medication
2024-01-09
ELSE PRESS RELEASES FROM THIS DATE:
Alzheimer Europe adopts position on anti-amyloid therapies for Alzheimer’s disease, issuing a call to action for timely, safe and equitable access
2024-01-09
Luxembourg, 9 January 2024 – In a new position paper, and following engagement with its national members and the European Working Group of People with Dementia (EWGPWD), Alzheimer Europe calls for concrete actions to enable timely, safe and equitable access to anti-amyloid drugs, for patients who are most likely to benefit from these innovative new treatments for Alzheimer’s disease (AD).
The growing prevalence and impact of AD has catalysed huge investments in research on its causes, diagnosis, treatment and care. After many high-profile ...
Improved cellular recycling could benefit patients with neurodegenerative conditions
2024-01-09
For the first time, a research team at The Hospital for Sick Children (SickKids) has uncovered a way to potentially reduce the amount of toxic cellular waste accumulating in patients with Zellweger Spectrum Disorder (ZSD).
ZSD is a group of rare, neurodegenerative genetic conditions caused by genetic variations that reduce the number of peroxisomes – the parts of cells that are responsible for, among other tasks, breaking down fats. ZSD varies in severity and is characterized by progressive neurodegeneration as well as symptoms that range from visual impairments, such as cataracts, to liver and kidney disfunction.
Like all living ...
Green ammonia could decarbonize 60% of global shipping when offered at just 10 regional fuel ports
2024-01-09
A study published today in IOP Publishing’s journal Environmental Research: Infrastructure and Sustainability has found that green ammonia could be used to fulfil the fuel demands of over 60% of global shipping by targeting just the top 10 regional fuel ports. Researchers at the University of Oxford looked at the production costs of ammonia which are similar to very low sulphur fuels, and concluded that the fuel could be a viable option to help decarbonise international shipping by 2050.
Around USD 2 trillion will be needed to transition to a green ammonia fuel supply chain by 2050, primarily to finance ...
Samsung leads again in U.S. patents while Qualcomm leaps into second place; overall grants dip 3.4%
2024-01-09
New Haven, Conn., Jan. 9, 2024—U.S. patent grants declined 3.4% from 2022, the lowest level since 2019, and Samsung held onto the top spot for the second year in a row according to IFI CLAIMS Patent Services, world leader in tracking patent application and grant data.
IFI CLAIMS Patent Services is a Digital Science company that compiles and tracks data from the U.S. Patent and Trademark Office (USPTO) and other patent-issuing agencies around the globe. IFI translates its world-leading data into an annual U.S. Top 50 and IFI Global 250 patent rankings, providing valuable insights into companies’ R&D activity.
Other findings in IFI’s latest rankings include patent powerhouse ...
Severe MS predicted using machine learning
2024-01-09
A combination of only 11 proteins can predict long-term disability outcomes in multiple sclerosis (MS) for different individuals. The identified proteins could be used to tailor treatments to the individual based on the expected severity of the disease. The study, led by researchers at Linköping University in Sweden, has been published in the journal Nature Communications.
“A combination of 11 proteins predicted both short and long-term disease activity and disability outcomes. We also concluded that it’s important to measure ...
Combining anti-tumor drugs with chemo may improve rare children’s cancer outcomes
2024-01-09
Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumour drugs as well as chemotherapy, a new trial has found.
The results of the BEACON trial conducted by the Cancer Research UK Clinical Trials Unit at the University of Birmingham found that combining anti-angiogenic drugs, which block tumours from forming blood vessels, alongside various chemotherapy drugs led to more young people seeing their tumours shrinking, from 18% in the control group to 26% among those on Bevacizumab.
The findings are published in the Journal of Clinical Oncology today. The trial saw 160 young ...
EBRAINS research infrastructure secures €38 million in funding for new phase of digital neuroscience
2024-01-09
The European Commission has accepted the EBRAINS 2.0 proposal submitted in response to the INFRASERV call, granting €38 million for the further development of services of the EBRAINS research infrastructure.
The European Commission has signed a grant agreement to fund EBRAINS with €38 million until 2026. Over the next three years, the infrastructure will continue to develop tools and services to widely serve research communities in neurosciences, brain medicine, and brain-inspired technologies.
EBRAINS (European Brain Research Infrastructures) is an EU co-funded collaborative research platform designed to advance neuroscience and brain ...
Train your brain to overcome tinnitus
2024-01-09
An international research team has shown that the debilitating impact of tinnitus can be effectively reduced in just weeks by a training course and sound therapy delivered via a smartphone app.
The team from Australian, New Zealand, French and Belgian universities report these findings today in Frontiers in Audiology and Otology.
It offers some hope for millions affected by tinnitus who:
have been told that there is nothing they can do about it
face long queues waiting for treatment, or
can’t afford the costs of specialist support.
The initial trial worked with 30 sufferers, of whom almost two thirds experienced a ‘clinically ...
A chemical reaction key to various industries just got greener
2024-01-09
Osaka, Japan – From alleviating your allergy symptoms to optimizing herbicide performance, alkylamines are molecules that have many uses. Unfortunately, common methods of producing alkylamines result in harmful waste byproducts. A method of synthesizing alkylamines in a sustainable yet cost-effective way has thus been highly sought after.
Now, in a study recently published in Green Chemistry, a research team led by Osaka University has found a way. The team has developed a method of alkylamine synthesis that works under mild conditions and produces ...
Spanish butterflies better at regulating their body temperature than their British cousins
2024-01-09
Butterfly populations in Catalonia in northern Spain are better than their UK counterparts at regulating their body temperature by basking in the sunshine, but rising global temperatures due to climate change may put Spanish butterflies at greater risk of extinction.
An international study, led by the University of Cambridge and the Institut de Biologia Evolutiva (IBE) in Barcelona, found that butterflies use different methods to regulate their body temperature. In Catalonia, butterflies tend to angle ...
LAST 30 PRESS RELEASES:
What are they vaping? Study reveals alarming surge in adolescent vaping of THC, CBD, and synthetic cannabinoids
ECMWF - delivering forecasts over 10 times faster and cutting energy usage by 1000
Brazilian neuroscientist reveals how viral infections transform the brain through microscopic detective work
Turning social fragmentation into action through discovering relatedness
Cheese may really be giving you nightmares, scientists find
Study reveals most common medical emergencies in schools
Breathable yet protective: Next-gen medical textiles with micro/nano networks
Frequency-engineered MXene supercapacitors enable efficient pulse charging in TENG–SC hybrid systems
Developed an AI-based classification system for facial pigmented lesions
Achieving 20% efficiency in halogen-free organic solar cells via isomeric additive-mediated sequential processing
New book Terraglossia reclaims language, Country and culture
The most effective diabetes drugs don't reach enough patients yet
Breast cancer risk in younger women may be influenced by hormone therapy
Strategies for staying smoke-free after rehab
Commentary questions the potential benefit of levothyroxine treatment of mild hypothyroidism during pregnancy
Study projects over 14 million preventable deaths by 2030 if USAID defunding continues
New study reveals 33% gap in transplant access for UK’s poorest children
Dysregulated epigenetic memory in early embryos offers new clues to the inheritance of polycystic ovary syndrome (PCOS)
IVF and IUI pregnancy rates remain stable across Europe, despite an increasing uptake of single embryo transfer
It takes a village: Chimpanzee babies do better when their moms have social connections
From lab to market: how renewable polymers could transform medicine
Striking increase in obesity observed among youth between 2011 and 2023
No evidence that medications trigger microscopic colitis in older adults
NYUAD researchers find link between brain growth and mental health disorders
Aging-related inflammation is not universal across human populations, new study finds
University of Oregon to create national children’s mental health center with $11 million federal grant
Rare achievement: UTA undergrad publishes research
Fact or fiction? The ADHD info dilemma
Genetic ancestry linked to risk of severe dengue
Genomes reveal the Norwegian lemming as one of the youngest mammal species
[Press-News.org] Different biological variants discovered in Alzheimer's diseaseResearch from Amsterdam UMC could be essential in the evaluation of future medication